Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test

     Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test

Conference Call and Webcast Tomorrow, March 13, 2014, 8:30am ET

PR Newswire

CASTLE ROCK, Colo., March 12, 2014

CASTLE ROCK, Colo., March 12, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq:
APPY), an in vitro diagnostic company focused on obtaining FDA clearance for
and commercializing its CE Marked APPY1™ Test, a rapid, multiple
biomarker-based assay for identifying patients that are at low risk for
appendicitis, today announced it will host a conference call to discuss
top-line results from its pivotal study of the APPY1 Test tomorrow, Thursday,
March 13, 2014, at 8:30 a.m. ET. The conference call will be hosted by Steve
Lundy, Chief Executive Officer.

Interested participants and investors may access the conference call by
dialing 1-877-870-4263 (U.S.), 1-855-669-9657 (Canada) or 1-412-317-0790
(international). A live audio webcast will be accessible via the Investor
Relations section of the Venaxis web site,

A telephonic replay of the call will be available for 90 days beginning
approximately one hour after the end of the conference call through June 13,
2014. Access numbers for this replay are 1-877-344-7529 (U.S./Canada) and
1-412-317-0088 (international); conference ID: 10042671. The webcast replay
will remain available in the Investors Relations section of the Venaxis web
site for 90 days.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical
development and commercialization of its CE Marked APPY1 Test, the Company's
rapid, protein biomarker-based assay for appendicitis. This unique
appendicitis test has projected high sensitivity and negative predictive value
and is being developed to aid in the identification of patients at low risk
for acute appendicitis, allowing for more conservative patient management.
The APPY1 Test is being developed initially for pediatric, adolescent and
young adult patients with abdominal pain, as this population is at the highest
risk for appendicitis and has the highest risk of long-term health effects
associated with CT imaging. While FDA clearance is being sought, a commercial
launch for the APPY1 Test is ongoing in select European countries. For more
information, visit

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc.
("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All
statements, other than statements of historical fact, included in this press
release that address activities, events or developments that Venaxis believes
or anticipates will or may occur in the future are forward-looking statements.
These statements are based on certain assumptions made based on experience,
expected future developments and other factors Venaxis believes are
appropriate in the circumstances. Such statements are subject to a number of
assumptions, risks and uncertainties, many of which are beyond the control of
Venaxis. Investors are cautioned that any such statements are not guarantees
of future performance. Actual results or developments may differ materially
from those projected in the forward-looking statements as a result of many
factors, including our ability to successfully complete required product
development and modifications in a timely and cost effective manner, complete
clinical trial data analysis and related activities for the APPY1  Test
required for FDA submission, obtain FDA clearance or approval, maintain CE
Marking, cost effectively manufacture and generate revenues from the APPY1 
Test at a profitable price point, execute agreements required to successfully
advance the company's objectives, retain the management team to advance the
products, overcome adverse changes in market conditions and the regulatory
environment, obtain and enforce intellectual property rights, and realize
value of intangible assets. Furthermore, Venaxis does not intend (and is not
obligated) to update publicly any forward-looking statements. The contents of
this press release should be considered in conjunction with the risk factors
contained in Venaxis' recent filings with the SEC, including its Form 10-Q for
the quarter ended June 30, 2013.

Venaxis and APPY1 are trademarks of Venaxis, Inc.

For Investors and Media:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, PhD; (212) 375-2664

Claire Sojda; (212) 375-2686

SOURCE Venaxis, Inc.

Press spacebar to pause and continue. Press esc to stop.